Drug Profile


Alternative Names: Anti-Blys/anti-APRIL fusion protein; TACI-Ig

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator ZymoGenetics
  • Developer EMD Serono; Merck Serono; ZymoGenetics
  • Class Antirheumatics; Recombinant fusion proteins
  • Mechanism of Action B cell activating factor inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Systemic lupus erythematosus
  • Phase II IgA nephropathy
  • Discontinued Chronic lymphocytic leukaemia; Lupus nephritis; Multiple myeloma; Multiple sclerosis; Non-Hodgkin's lymphoma; Rheumatoid arthritis

Most Recent Events

  • 31 Jan 2017 Phase-II clinical trials in IgA nephropathy in USA (SC) (NCT02808429)
  • 14 Nov 2016 Efficacy, immunogenicity and adverse events data from the phase IIb ADDRESS II trial in Systemic lupus erythematosus released by Merck
  • 11 Nov 2016 Efficacy data from a phase II trial in Systemic lupus erythematosus presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top